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Objectives
All HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and  F2 fibrosis
should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment
uptake among coinfected patients in Europe.
Methods
EuroSIDA patients with viraemic HCV infection were included in the study. Poisson regression
was used to identify temporal changes and regional differences in HCV treatment uptake.
Results
A total of 1984 patients were included in the study, with a median follow-up time of 168
months [interquartile range (IQR) 121–204 months]. To date, 501 (25.3%) HIV/HCV-coinfected
patients have received HCV therapy. Treatment incidence rose from 0.33 [95% confidence
interval (CI) 0.16–0.50] per 100 person-years of follow-up (PYFU) in 1998 to 5.93 (95% CI
4.49–7.38) in 2007, falling to 3.78 (95% CI 2.50–5.07) in 2009. After adjustment, CD4 cell count
> 350 cells/mL [incidence rate ratio (IRR) 1.33 (95% CI 1.06–1.67) vs. CD4 count 200-350
cells/mL] and F2 liver fibrosis [IRR 1.60 (95% CI 1.14–2.25; P = 0.0065) vs. < F2 fibrosis] were
predictors of anti-HCV treatment initiation. However, 22% of patients who remain untreated for
HCV, with fibrosis data available, had F2 fibrosis and should have been considered for
treatment, while only 36% of treated patients had F2 fibrosis.
Conclusions
Although treatment incidence for HCV has increased, there remain a large proportion of patients
indicated for treatment who have yet to be treated.
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Introduction
The substantial declines in HIV-related mortality, as a con-
sequence of the introduction of combination antiretroviral
therapy (cART), have seen liver-related mortality assume
increasing importance among HIV-positive individuals
[1–3]. Progression of liver disease is common with hepatitis
C virus (HCV) infection and known to be accelerated in the
presence of HIV [4,5]. According to current guidelines, all
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coinfected patients with chronic HCV infection and signifi-
cant fibrosis (F2) should be considered for HCV therapy
given their increased risk of death from liver disease [6,7].
HCV treatment should preferentially be offered to patients
with controlled HIV infection, and therefore it is recom-
mended when CD4 cell counts are above 350 cells/mL and
often deferred when counts are below 200 cells/mL [7].
However, patients with CD4 cell counts below 200 cells/mL
have been shown to respond well to HCV treatment when
HIV replication is suppressed [8]. Despite these recommen-
dations, the extent to which HIV/HCV-coinfected patients
start HCV therapy is not well documented in Europe. Pre-
vious studies from 2003–2006, including a EuroSIDA
study, have shown that a low proportion of patients are
initiating anti-HCV therapy, typically less than 10% [9–12].
This study includes data up to 2010, when the gold
standard treatment for HCV infection was a combination
of pegylated interferon (peg-IFN) and ribavirin [6]. How-
ever, HCV treatment is not generally well tolerated and
response-guided therapy is used to determine whether
treatment should continue for the full duration [7].
The aims of this study were to describe the temporal
changes and regional differences in the uptake of anti-
HCV therapy and to identify factors associated with treat-
ment across Europe, documenting the rate of completion
of full treatment duration and factors that predict com-
pleting therapy. In a subset of patients with available data,
we also aimed to identify whether patients with significant
fibrosis, in most urgent need of treatment, were selected
for treatment.
Study participants
The EuroSIDA study is a large prospective, observational
cohort study of 18 295 HIV-positive individuals in 105
centres across Europe, Israel and Argentina. The study has
been described in detail previously [13]. HCV antibody
(HCVAb) status has been collected since 1997; persons
who died or were lost to follow-up before this date did
not routinely have HCVAb status collected. Centres that
have determined HCV genotype or measured HCV RNA are
requested to provide that information to the coordinating
centre. Information on the collection of HCVAb, HCV RNA
and genotype data has been given in detail elsewhere
[14,15].
Data on alanine transaminase (ALT), aspartate transami-
nase (AST) and platelet counts have been collected since
1999 and 2005, respectively, while data on liver biopsy
and Fibroscan® (Echosens S.A.S.U, Paris, France) [16] have
been collected since 2010, with sites requested to list all
previous test results where liver biopsy was graded using
the METAVIR scoring system [17] and return the histologi-
cal report for internal validation. Plasma hyaluronic acid
(HA) has been measured in all HCVAb-positive patients
with stored plasma samples; HA data collection is described
elsewhere [18].
Statistical methods
All HCVAb-positive individuals positive for quantitative
HCV RNA were included in these analyses. Baseline was
defined as the date of first HCVAb-positive test result
or recruitment to EuroSIDA, whichever occurred later. In
analyses with the outcome of initiating HCV therapy,
patients were followed up to their last visit, death or the
date of starting HCV therapy, defined as treatment with at
least interferon-a (peg-IFN) plus or minus ribavirin.
Trends over time in starting HCV therapy were described
using Poisson regression models. Factors associated with
HCV treatment uptake were investigated in univariable
analyses and those that were significant with P < 0.1 were
included in multivariable models. Investigated factors
included age, gender, ethnic group, region of Europe,
HIV transmission risk group, prior AIDS diagnosis, time-
updated CD4 cell count, time-updated HIV RNA, time-
updated HCV RNA, HCV genotype, time-updated hepatitis
B virus surface antigen (HBsAg) status, starting cART,
calendar year and time-updated alanine transaminase
(ALT) levels.
Fibrosis levels among treated and untreated patients
were summarized. As fibrosis progression rates have been
shown to be slow in this population [19], fibrosis markers
up to 2 years prior to initiation of HCV treatment were
included, along with the last available measurement in
those who remained untreated. The proportions of treated
and untreated patients with significant fibrosis were
compared using a combined definition of F2 fibrosis
from biopsy and Fibroscan, HA > 100 ng/mL and an AST
to platelet ratio index (APRI [20]) > 1.5, which have
been shown to be accurate markers of significant fibrosis
[21,22]. A Fibroscan reading of > 7.6 kPa was used to
identifyF2 fibrosis, in accordance with a recent review of
the subject [23].
Completion of a full course of HCV therapy is defined
dependent on HCV genotype, with a ‘full course’ considered
to have been completed after a minimum of 48 weeks for
genotype 1 or 4 and after a minimum of 24 weeks for
genotype 2 or 3 [6]. However, because patients may have
shorter treatment duration in the clinical setting, we also
considered patients who completed at least 80% of the
expected minimum treatment duration to have completed
therapy, in line with previous studies concerning HCV
treatment duration (i.e. 38.4 weeks for genotype 1 or 4 and
19.2 weeks for genotype 2 or 3) [24,25]. The median length
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of treatment duration by HCV genotype, along with the
percentage of patients completing a full course of treatment,
were determined in patients with known HCV genotype and
sufficient follow-up to have completed 80% of treatment.
Predictors of completing a full course of HCV therapy
were determined using logistic regression models adjusted
for age, gender, ethnic group, HIV transmission group,
region of Europe, baseline cART use, prior AIDS diagnoses,
HCV genotype, CD4 cell count at treatment initiation, HIV
viral load at treatment initiation, HCV viral load at treat-
ment initiation and calendar year of treatment initiation.
All analyses were performed using SAS (version 9.2; SAS
Institute, Cary, NC).
Results
Of the 4224 HCVAb-positive patients in EuroSIDA, 2633 had
available HCV RNA measurements, of whom 2008 (76.3%)
were HCV RNA positive and 1984 either never received
HCV therapy or did so after baseline and were eligible
for inclusion in this analysis. Median follow-up time was
168 months [interquartile range (IQR) 121–204 months]. In
multivariable logistic regression, HCVAb-positive patients
without HCV RNA data available compared to those with
HCV RNA data available had lower CD4 cell counts at
baseline [adjusted odds ratio (aOR) 0.91 (95% confidence
interval (CI) 0.87–0.96; P = 0.0002) per doubling], were
more likely to come from Eastern Europe [aOR 6.45 (95% CI
4.63–8.99; P < 0.0001) comparedwith Southern Europe] and
were recruited to EuroSIDA later [aOR 1.09 (95% CI 1.07–
1.12; P < 0.0001) per year later].
Table 1 shows the patient characteristics at baseline and
at the date of HCV treatment initiation or last follow-up
according to whether treated for HCV infection. A higher
proportion of treated patients resided in Southern Europe
(41.1% vs. 33.0% for untreated patients; P = 0.0039) and
belonged to the men who have sex with men (MSM) HIV
transmission group (12.1% vs. 8.4%, respectively), while a
lower proportion of treated patients belonged to the inject-
ing drug use (IDU) HIV transmission group (68.9% vs.
74.5%, respectively; global P = 0.09). At the time of anti-
HCV treatment initiation or last follow-up for those not
Table 1 Patient characteristics at baseline and date of last follow-up or hepatitis C virus (HCV) treatment
At baseline At last follow-up or treatment
Untreated
(n = 1483)
Treated
(n = 501) P-value*
Untreated
(n = 1483)
Treated
(n = 501) P-value*
Age (years) [median (IQR)] 33 (28-38) 32 (28–37) 0.29 44 (37–49) 41 (35–46) < 0.0001
Male (%) 67.9 72.6 0.048
White (%) 91.5 93.1 0.27
Region of Europe (%) South 33 41.1 0.0039
West Central 21.6 18.1
North 17.5 12.9
East Central 16.2 17.7
East 11.7 10.3
HIV transmission group (%) MSM 8.4 12.1 0.09
IDU 74.5 68.9
Haemophiliac 3.6 4.2
Heterosexual 10.4 11.7
Other 3.1 3.2
HCV genotype (%) 1 45.2 41.2 0.084
2 2.8 2.2
3 23.4 28.8
4 11.9 13.5
Unknown 16.7 14.5
HBsAg status (%) Negative 60.8 65.1 0.21 85 88.7 0.12
Positive 4.3 4.2 8.3 6.2
Unknown 34.9 30.8 6.7 5.2
Started cART (%) 21.1 26.4 0.014 86.7 86.3 0.85
ALT [units/litre (U/L)] n (%) 418 (28.2) 38 (7.6) 1308 (88.2) 409 (81.6)
Median (IQR) 51 (26–83) 49.5 (30–106) 0.44 44 (37–49) 76 (49–120) < 0.0001
CD4 count (cells/mL) [median (IQR)] 268.5 (145–400) 290 (158.5–429) 0.017 391 (227–614) 479 (349–650) < 0.0001
HIV RNA < 500 copies/mL [% (95% CI)] 26.8 (24.5–29.1) 34.3 (30.2–38.5) 0.0013 71.2 (68.8–73.5) 80.3 (76.7–83.9) < 0.0001
HCV RNA < 800 000 IU/mL [% (95% CI)] 57.8 (55.3–60.3) 59.7 (55.4–64.0) 0.45 55.9 (53.4–58.5) 57.9 (53.2–62.6) 0.46
ALT, alanine transaminase; cART, combination antiretroviral therapy; CI, confidence interval; HBsAg, hepatitis B virus surface antigen; IDU, injecting drug
use; IQR, interquartile range; MSM, men who have sex with men.
*P-values for comparison of proportions or medians.
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yet treated, ALT levels were higher in treated patients
[median 76 (IQR 49-120) vs. 44 (37–49) U/L for untreated
patients; P < 0.0001], as were CD4 cell counts [median 479
(IQR 349– 650) vs. 391 (227–614) cells/mL, respectively;
P < 0.0001].
Uptake of HCV therapy
In total, 501 of 1984 patients (25.3%) have so far received
HCV therapy in 18 303 person-years of follow-up (PYFU),
giving an overall incidence of treatment of 2.74 per 100
PYFU (95% CI 2.50–2.97). Figure 1 shows how the inci-
dence of treatment has changed over time. The overall
incidence of treatment increased from 0.33 per 100 PYFU
(0.16–0.50) in 1998 to 5.93 (4.49–7.38) in 2007 before
falling to 3.78 (2.50–5.07) in 2009. In univariable Poisson
regression models, the incidence of treatment increased
by 27% per year (95% CI 23–31%; P < 0.0001) between
1998 and 2007, and fell by 12% per year (95% CI 2-21%;
P = 0.020) between 2007 and 2010.
Table 2 shows univariable and multivariable Poisson
regression parameter estimates for predictors of HCV treat-
ment. In multivariable models, patients selected for treat-
ment were more likely than untreated patients to reside
in Southern Europe [incidence rate ratio (IRR) 1.38 (95%
CI 1.06–1.82; P = 0.019) compared with Western Europe]
and belong to the MSM HIV transmission group [IRR 1.36
(95% CI 1.00–1.83; P = 0.046) compared with IDU]. Treated
patients were also more likely to have current CD4
cell counts > 350 cells/mL [IRR 1.33 (95% CI 1.06–1.67;
P = 0.013) compared with CD4 counts between 200 and 350
cells/mL] and less likely to have CD4 cell counts < 200
cells/mL [IRR 0.42 (0.27–0.65; P = 0.0001) compared with
CD4 counts between 200 and 350 cells/mL].
Compared with untreated patients, treated patients more
often had current HIV RNA levels below 500 HIV-1 RNA
copies/mL [IRR 1.39 (95%CI 1.07–1.80; P = 0.012) compared
with HIV RNA > 500 copies/mL], indicating well-controlled
HIV infection with cART. At the time of treatment, treated
patients were also more likely than untreated patients to
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Fig. 1 Temporal change in the incidence of uptake of hepatitis C virus (HCV) treatment. The incidence rate ratio (IRR) was calculated from univariable
Poisson regression. CI, confidence interval; PYFU, person-years of follow-up.
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have HCV RNA > 800 000 IU/mL [IRR 1.21 (95% CI 1.00–
1.47; P = 0.049) compared with HCV RNA between 616 and
800 000 IU/mL] and raised ALT levels [upper normal range
(uNR) < ALT < 3 times uNR, IRR 2.33 (95% CI 1.83–2.96;
P < 0.0001); ALT > 3 times uNR, IRR 3.56 (95% CI 2.61–4.86;
P < 0.0001) compared with ALT within the normal range]. In
the multivariable model, the calendar year effect was similar
to that shown in Figure 1, with the incidence of treatment
increasing until the years 2007–2008 before falling in
2009–2010. However, in the multivariable model, taking
changes in patient characteristics into account, changes in
the incidence of treatment from 2003/2004 onwards were
not significant [2005/2006, IRR 0.97 (95% CI 0.73–1.29;
P = 0.85); 2007/2008, IRR 1.28 (95% CI 0.98–1.68; P =
0.074), and 2009/2010, IRR 0.82 (95% CI 0.61–1.11; P = 0.20)
compared with 2003/2004].
The proportion of patients treated for HCV infection did
not differ greatly for HCV genotypes 1 to 4 (23.6, 21.2, 29.5
and 27.8%, respectively; P = 0.084). Removing patients
who contracted HIV infection via the MSM route, on the
assumption that they were acutely infected with HCV, did
not change the proportions treated (23.2, 20.9, 28.0 and
26.2%, respectively; P = 0.29), and in the multivariable
model HCV genotype was not significantly associated with
treatment initiation (Table 2).
Interactions between calendar year and region of Europe
(P = 0.48) and calendar year and HIV transmission group
(P = 0.80) were both nonsignificant, indicating that there
were no significant differences in the increasing incidence
of HCV treatment uptake across regions of Europe and HIV
transmission groups, although the power to detect such
differences was limited.
Liver fibrosis levels
Fibrosis markers were available in 800 of 1984 patients
(40.3%) included in this study and are summarized in
Table 3. Patients without fibrosis data were more likely to
be MSM [odds ratio (OR) 1.53 (95% CI 1.07–2.18; P = 0.019)
vs. IDU], reside in Northern Europe [OR 1.54 (95% CI
1.12–2.13; P = 0.0007) vs. Western Europe] and have
lower CD4 cell counts at treatment or last follow-up
[OR 0.72 (95% CI 0.67–0.79; P < 0.0001) per doubling].
Similar proportions of treated and untreated patients with
biopsy/Fibroscan data available had F2 fibrosis (43.9%
Table 2 Univariable and multivariable Poisson parameter estimates for factors associated with anti-hepatitis C virus (HCV) treatment initiation
Variable
Univariable Multivariable
Estimate
95% confidence
interval P-value Estimate
95% confidence
interval P-value
Calendar year: 1998 vs. 2003–2004 0.07 (0.04–0.12) < 0.0001 0.11 (0.06–0.21) < 0.0001
1999–2000 vs. 2003–2004 0.48 (0.34–0.68) < 0.0001 0.43 (0.29–0.65) 0.0001
2001–2002 vs. 2003–2004 0.89 (0.68–1.16) 0.39 0.65 (0.47–0.89) 0.0074
2005–2006 vs. 2003–2004 1.72 (1.37–2.15) < 0.0001 0.97 (0.73–1.29) 0.85
2007–2008 vs. 2003–2004 2.65 (2.15–3.27) < 0.0001 1.28 (0.98–1.68) 0.074
2009–2010 vs. 2003–2004 1.68 (1.33–2.12) < 0.0001 0.82 (0.61–1.11) 0.20
South vs. West Central Europe 1.17 (0.98–0.40) 0.081 1.38 (1.06–1.82) 0.019
North vs. West Central Europe 0.74 (0.57–0.95) 0.021 1.02 (0.73–1.44) 0.89
East Central vs. West Central Europe 1.20 (0.96–1.51) 0.12 1.03 (0.74–1.43) 0.85
East vs. West Central Europe 1.38 (1.03–1.84) 0.030 1.18 (0.78–1.78) 0.45
Started cART* 3.29 (2.54–4.26) < 0.0001 1.33 (0.93–1.90) 0.12
CD4 count < 200 cells/mL* vs. CD4 count 200-350 cells/mL 0.21 (0.14–0.32) < 0.0001 0.42 (0.27–0.65) 0.0001
CD4 > 350 cells/mL* vs. CD4 count 200-350 cells/mL 2.86 (2.35–3.48) < 0.0001 1.33 (1.06–1.67) 0.013
HIV RNA < 500 copies/mL* vs.  500 copies/mL 3.08 (2.51–3.78) < 0.0001 1.39 (1.07–1.80) 0.012
HCV RNA > 800 000 IU/mL* vs. HCV RNA 616 to 800 000 IU/mL 1.90 (1.59–2.29) < 0.0001 1.21 (1.00–1.47) 0.049
MSM vs. IDU 1.48 (1.13–1.94) 0.0042 1.36 (1.00–1.83) 0.046
Heterosexual vs. IDU 1.17 (0.89–1.53) 0.27 1.19 (0.90–1.59) 0.22
Other vs. IDU 1.07 (0.76–1.51) 0.68 1.25 (0.88–1.78) 0.21
HCV genotype 2 vs. HCV genotype 1 0.75 (0.41–1.36) 0.35 1.05 (0.56–1.94) 0.89
HCV genotype 3 vs. HCV genotype 1 1.26 (1.04–1.53) 0.018 1.20 (0.96–1.49) 0.11
HCV genotype 4 vs. HCV genotype 1 1.09 (0.84–1.41) 0.51 1.20 (0.90–1.59) 0.21
HCV genotype unknown vs. HCV genotype 1 0.92 (0.72–1.19) 0.53 1.02 (0.77–1.34) 0.91
NR < ALT < 3 times NR vs. upper limit NR 2.93 (2.46–3.49) < 0.0001 2.33 (1.83–2.96) < 0.0001
ALT > 3 times NR vs. upper limit NR 3.39 (2.65–4.34) < 0.0001 3.56 (2.61–4.86) < 0.0001
ALT unknown vs. upper limit NR 0.25 (0.20–0.31) < 0.0001 1.62 (1.17–2.25) 0.0039
The model was also adjusted for age, gender, race and hepatitis B virus surface antigen (HBsAg) status.
ALT, alanine transaminase; cART, combination antiretroviral therapy; IDU, injecting drug use; MSM, men who have sex with men; NR, normal range for ALT,
defined as < 50 U/L for men and < 40 U/L for women; 3 times NR, 3 times the normal range.
*Time-updated variable.
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vs. 40.8%, respectively; P = 0.65). Median HA levels
were higher among treated patients (41.2 vs. 28.4 ng/
mL, respectively; P = 0.015) and a higher proportion also
had HA > 100 ng/mL (25.5% vs. 12.3%, respectively;
P = 0.011). There was no statistical difference between the
median APRI score of treated patients and that of untreated
patients (0.78 vs. 0.94, respectively; P = 0.63), or the
proportion of patients with APRI scores > 1.5 (24.1% vs.
29.0%, respectively; P = 0.55).
Using a combined definition including all available
fibrosis data, a higher proportion of patients treated for
HCV infection were found to have significant fibrosis
compared with those yet to be treated (41.3% vs. 31.7%,
respectively; P = 0.031). In a sensitivity analysis addition-
ally adjusting the model in Table 2 for the time-updated
level of fibrosis, patients with F2 fibrosis were 60%
more likely to be treated [IRR 1.60 (95% CI 1.14–2.25;
P = 0.0065) vs. < F2 fibrosis]. Among those with data, only
36.0% of patients who were treated for HCV infection had
significant fibrosis indicating treatment, while 22.0% of
patients untreated for HCV had significant fibrosis
(Table 3). Both the majority of patients treated for HCV
infection without significant fibrosis and the majority
of patients with significant fibrosis untreated for HCV
infection resided in Southern Europe (41.7% and 46.2%,
respectively; Table 3), not unexpectedly, as the majority of
patients included in the study were from Southern Europe.
However, after additionally adjusting for the interaction
between the level of fibrosis and region of Europe in the
model in Table 2, we found that patients with F2 fibrosis
were less likely to be treated in Southern Europe [IRR 0.37
(95% CI 0.17–0.82; P = 0.014)] and Northern Europe [IRR
0.32 (95% CI 0.11–0.97; P = 0.044)] compared with Western
Europe. Although IDU was not found to be associated with
treatment in this model, 77% of patients with significant
fibrosis who were not treated were IDU.
Completion of full HCV treatment duration
Figure 2 shows the median treatment duration in weeks
and the percentage of patients who completed at least 80%
of full treatment duration by HCV genotype. After remov-
ing those with unknown HCV genotype, 271 of 416 patients
(65.1%) completed HCV treatment. In multivariable logistic
regression assessing factors associated with completing at
least 80% of full HCV treatment duration, patients who
were younger [aOR 0.70 (95% CI 0.50–0.98; P = 0.038)
per 10 years], with HCV genotype 2/3 [aOR 3.31 (95% CI
1.92–5.70; P < 0.0001) vs. HCV genotype 1] and HIV RNA
< 500 copies/mL at treatment initiation [aOR 2.25 (95% CI
1.22–4.17; P = 0.0095) compared with HIV RNA  500
copies/mL], were more likely to complete a full course
of HCV therapy. There was also borderline evidence to
suggest that patients with CD4 cell counts < 200 cells/mL at
Table 3 Fibrosis marker information prior to hepatitis C virus (HCV) treatment and at last available measurement for those untreated for HCV
infection
Fibrosis marker
Treated
(n = 501)
Untreated†
(n = 1154) P-value
Fibroscan/biopsy n (%) 66 (13.2) 184 (15.9)
< F2 37 (56.1) 109 (59.2) 0.65
F2 29 (43.9) 75 (40.8)
Hyaluronic acid n (%) 47 (9.4) 488 (42.3)
Median (IQR) (ng/mL) 41.2 (23.4–106.9) 28.4 (15.2–59.9) 0.015
n (%) > 100 ng/mL 12 (25.5) 60 (12.3) 0.011
APRI n (%) 54 (10.8) 62 (5.4)
Median (IQR) 0.78 (0.48–1.47) 0.94 (0.46–1.72) 0.63
n (%) > 1.5 13 (24.1) 18 (29.0) 0.55
Any marker n (%) 150 (29.9) 650 (56.3)
Significant fibrosis* 54 (36.0) 143 (22.0) 0.0003
Distribution of mismatched patients
(treated without significant fibrosis and untreated
with significant fibrosis)
n (%) 96 143
South 40 (41.7) 66 (46.2)
West 14 (14.6) 27 (18.9)
North 7 (7.3) 28 (19.6)
East 27 (28.1) 13 (9.1)
East Central 8 (8.3) 9 (6.3)
Time prior to treatment/last follow-up that fibrosis
measurement was taken
Median (IQR) (months) 5.7 (2.7–11.9) 57.1 (12.2–110.9) < 0.0001
For treated patients, fibrosis data were included up to 2 years prior to treatment initiation; for untreated patients, the last available measurement was used.
APRI, aspartate transaminase to platelet ratio index; IQR, interquartile range.
*Significant fibrosis defined using a combined definition of any of F2 fibrosis from Fibroscan/biopsy, HA > 100 ng/mL or APRI > 1.5.
†Untreated patients who were alive at last follow-up.
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treatment initiation were more likely to complete therapy
[aOR 3.24 (95% CI 0.99–10.59; P = 0.051) vs. CD4 count
between 200 and 350 cells/mL].
Forty-four of 416 patients (10.6%) discontinued treat-
ment before completing 12 weeks of therapy. In a multi-
variable logistic regression model with the endpoint of
discontinuing HCV treatment before 12 weeks of therapy,
baseline cART use was associated with a 74% reduction in
early HCV treatment termination [aOR 0.26 (95% CI 0.09–
0.74; P = 0.012)].
Discussion
Twenty-five per cent of HCV viraemic patients were treated
for HCV infection in EuroSIDA between 1998 and 2010.
This is a higher proportion than has been reported in other
studies where treatment uptake was low [9,10,12,25,26].
One of the strengths of this study is that we were able to
characterize HCV status using HCVAb and HCV RNA in a
large number of patients over a long period of time. In the
absence of HCV RNA data, the proportion of patients
selected for treatment is likely to be underestimated as
the denominator will include aviraemic HCVAb-positive
patients. This, along with the length of follow-up (median
168 months) in the current study, explains the increase
in treatment uptake observed compared with a previous
EuroSIDA study (7.6%), which categorized patients as
HCV positive based solely on HCV antibody testing [11],
and another previous European study (12%) with a median
follow-up of 72 months [26].
In univariable models the incidence of anti-HCV treat-
ment uptake increased by 27% per year between 1998 and
2007 before falling by 12% per year between 2007 and 2010,
while in multivariable analysis the changes after 2003/2004
were not statistically significant. The increasing uptake
of anti-HCV therapy probably reflects the introduction of
peg-IFN, with cure rates of approximately 70% for HCV
genotype 2 or 3 and 35% for genotype 1 or 4 [8,27–29]. The
trend of decreasing treatment uptake seen after a peak in
2007 is explained by different patient characteristics and
possibly treatment saturation of the easy-to-treat patients
eligible for interferon therapy, with patients and physicians
choosing to wait for the first generation of directly acting
agents for HCV. With positive predictors of HCV treatment
success including younger age, HCV RNA < 800 000 IU/mL
and non-HCV genotype 1, clinicians and their patients with
low fibrosis stages, high HCV RNA or HCV genotype 1 may
feel that they should wait for more efficacious HCV therapy
on the horizon [30], potentially avoiding the unpleasant side
effects of treatment with interferon [31].
Patients initiating HCV therapy had CD4 cell counts
> 350 cells/mL, ALT values above the normal range and HIV
RNA levels < 500 copies/mL, in line with current treatment
guidelines [7]. HCV RNA levels > 800 000 IU/mL were also
associated with treatment uptake, even though high HCV
viral loads have been associated with a poor response to
treatment [32]. Interestingly, patients residing in Southern
compared with Western Europe and those belonging to the
MSM HIV transmission group compared with IDU were
also more likely to be treated. This does not seem to be
40.9
46.8
29.3 30.5
45.8
0
7
14
21
28
35
42
49
56
0
25
50
75
100
All genotypes
(n = 416)
1 (n = 196) 2 (n = 11) 3 (n = 141) 4 (n = 68)
Le
ng
th
 o
f t
re
at
m
en
t d
ur
at
io
n
[m
ed
ia
n 
(I
Q
R
),
 w
ee
ks
]
P
er
ce
nt
ag
e 
co
m
pl
et
in
g 
tr
ea
tm
en
t
HCV genotype (n with sufficient follow-up)
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explained by the HCV genotype distribution, as a similar
proportion of patients were treated in each of the HCV
genotype groups and the distribution of genotypes was
similar across all regions (results not shown). The higher
rate of treatment in Southern Europe could have a variety
of explanations. There may be greater clinician experience
of dealing with HIV/HCV coinfection in Southern Europe
because of the higher prevalence of HCV infection in that
region, but also differences in national guidelines and local
traditions. That Eastern Europe was not found to have
lower rates of treatment is probably attributable to the
inclusion criteria in this study; in particular, many patients
from that region were excluded as they did not have
available HCV RNA data. The observation that MSM were
more likely to be treated than IDU can be explained by
recent outbreaks of acute HCV infection in this patient
population [33,34], with treatment of acute HCV infection
associated with much better cure rates than treatment of
chronic HCV infection [35,36], while MSM are also con-
sidered to be more adherent to treatment, with IDU often a
contraindication of therapy.
We found that a higher proportion of patients treated for
HCV infection had significant fibrosis prior to treatment, as
evaluated using liver biopsy, Fibroscan, HA and APRI data,
compared with those yet to be treated at last follow-up.
In sensitivity analysis, significant fibrosis was associated
with a 60% increased incidence of treatment initiation;
however, only one-third of patients treated for HCV infec-
tion were known to have F2 fibrosis, while 22% of
untreated patients with fibrosis data had F2 fibrosis and
should have been considered for treatment. We allowed
a 2-year window prior to treatment for the fibrosis data
and used the last available measurement in patients yet to
be treated, so it is possible that some patients could have
progressed in this time prior to initiating therapy or last
follow-up. However, the median time prior to treatment for
fibrosis measurements was 5.7 months in treated patients
and progression rates have been shown to be slow [19]. The
median time prior to last follow-up for untreated patients
was 57 months and it is more likely that progression would
have taken place in these patients, meaning that it is
possible that we are underestimating the level of fibrosis
in untreated patients. We also found that patients with
significant fibrosis were less likely to be treated in South-
ern and Northern Europe compared with those with sig-
nificant fibrosis in Western Europe. Although fibrosis data
were only available in a subset of the study population,
this finding is likely to be at least partially explained by
unmeasured confounding where there is contraindication
to treatment, with 77% of untreated patients with F2
fibrosis being IDU. However, there is a need for focus on
correctly identifying eligible patients for therapy.
The median duration of HCV treatment was close to the
guideline minimum duration of therapy for HCV genotype
1 or 4 and surpassed it for genotype 2 or 3. However,
one-third of all patients started on therapy discontinued
before completing the full treatment duration, with the
lowest rates of completion for genotypes 1 and 4. The lower
proportion of patients completing 80% of full treatment
duration among patients with HCV genotype 1 or 4 reflects
the heightened difficulty in treating these patients, with
lower response rates and treatment termination expected
with response-guided therapy [7].
In adjusted logistic regression models, we found
that younger age, HCV genotype 2 or 3 and HIV RNA
< 500 copies/mL at HCV treatment initiation were associ-
ated with HCV treatment completion. Younger age and
HCV genotype 2 or 3 are well-known predictors of treat-
ment success [30], while controlling HIV infection with
cART, lowering HIV RNA and raising CD4 cell counts prior
to initiating HCV therapy is best practise to ensure the
highest chance of completing the full treatment duration,
in line with current HCV treatment guidelines [6,7]. We
also found that initiating cART early during clinical care
was associated with a lower rate of early HCV treatment
discontinuation.
A limitation to this study is that in practice many
patients may stop HCV treatment early because of adverse
events, on which we have no data, while others may not
be treated because of contraindication. Further, we have
described the rate of significant fibrosis where biopsy and
biomarker data are available. Although the biomarkers
considered are well described, they will be less precise than
biopsy at determining significant fibrosis and should be
interpreted accordingly.
In conclusion, we have reported an increase in the inci-
dence of treatment for HCV infection in EuroSIDA, with
those selected for treatment mostly aligned with current
treatment guidelines. However, there were marked regional
differences and important deviations from the guidelines,
as two-thirds of treated patients were without significant
fibrosis. We have also shown that younger age, HCV geno-
types 2 and 3 and undetectable HIV RNA at HCV treatment
initiation are all associated with completing HCV therapy.
Although 25% of those with documented viraemic HCV
infection have undergone anti-HCV treatment, there
remain patients, including some with significant fibrosis,
who have not been exposed to anti-HCV treatment. Future
studies of the reasons for this are warranted.
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